Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2014; 20(6): 1493-1502
Published online Feb 14, 2014. doi: 10.3748/wjg.v20.i6.1493
Table 1 Indications for Helicobacter pylori eradication in 2013 guidelines
Indications
ChinaStrongly recommended
Peptic ulcer (regardless of activeness or complications)
Gastric MALT lymphoma
Recommended
Chronic gastritis with dyspepsia
Chronic gastritis with mucosal atrophy/erosion
Early gastric cancer resected endoscopically or by subtotal gastrectomy
Long-term use of proton pump inhibitor
Family history of gastric cancer
Planning to take long-term NSAIDs (including low-dose aspirin)
Iron deficiency anemia of unknown causes
Idiopathic thrombocytopenic purpura
Other H. pylori-related diseases (lymphocytic gastritis, gastric hyperplastic polyps, Ménétrier disease, etc.)
Requested by individual patient
JapanApproved by the Japanese national health insurance system
Peptic ulcer disease
After resection of early gastric cancer
Gastric MALT lymphoma
Idiopathic thrombocytopenic purpura
H. pylori-related gastritis
South KoreaStrongly recommended
Peptic ulcer disease
Low-grade gastric MALT lymphoma
After resection of early gastric cancer
Recommended
Chronic atrophic gastritis or intestinal metaplasia
Family history of gastric cancer
Functional dyspepsia
Long-term aspirin/NSAIDs medication with history of peptic ulcer disease
Idiopathic thrombocytopenic purpura
Table 2 Diagnostic methods for Helicobacter pylori infection in 2013 guidelines
ChinaJapanSouth Korea
For initial diagnosisNon-invasive methodsUrea breath testSerum antibody testSerum antibody test
Stool antigen testUrea breath testUrea breath test
Stool antigen testStool antigen test
Invasive methodsRapid urease testRapid urease testRapid urease test
HistologyHistologyHistology
CultureCulture
Follow-up test after eradicationNon-invasive methodsUrea breath testSerum antibody test1Urea breath test
Stool antigen testUrea breath testStool antigen test
Stool antigen test
Invasive methodsRapid urease testRapid urease testRapid urease test
HistologyHistology
Culture
Table 3 Regimens for Helicobacter pylori eradication in 2013 guidelines
ChinaJapanSouth Korea
First-line treatment1Amoxicillin 1 g (or metronidazole 400 mg), clarithromycin 500 mg, and PPI twice daily for 7-14 dAmoxicillin 750 mg, clarithromycin 200 mg (or 400 mg), and PPI twice daily for 7 dAmoxicillin 1 g, clarithromycin 500 mg, and PPI twice daily for 7-14 d
Second-line treatmentBismuth 220 mg, tetracycline 750 mg, metronidazole 400 mg twice, and PPI twice daily for 10 or 14 dAmoxicillin 750 mg, metronidazole 250 mg, and PPI twice daily for 7 dBismuth 120 mg four times, tetracycline 500 mg four times, metronidazole 500 mg thrice, and PPI twice daily for 7-14 d
Table 4 Different characteristics of 2013 guidelines in three countries
CountryNotable differences in characteristics
Indication for eradicationChinaStrong recommendations do not include after resection of EGC. Intestinal metaplasia is not included in the indications
JapanAll infected subjects are included as “H. pylori-related gastritis”
Focus is on preventing dissemination
South KoreaStrong recommendations include only peptic ulcer disease, gastric MALT lymphoma, and after resection of EGC
Diagnostic methodChinaSerology is not recommended
Only the urea breath test is recommended after eradication
Invasive tests are not recommended after eradication
JapanEither two noninvasive tests or one invasive test is recommended
A decrease relative to the initial serum antibody level of more than 50% after 6-12 mo is considered the most reliable method
South KoreaBacterial culture is not included
Treatment regimenChinaDue to the high resistance to the antibiotics metronidazole, clarithromycin, and tetracycline, an alternative regimen is recommended
First-line treatment can be omitted in cases of clarithromycin resistance
JapanLower dose of antibiotics for shorter duration (7 d) than other countries
There is neither 14 d nor bismuth-based regimen in the first-line and second-line treatment
South KoreaFirst-line treatment can be omitted in cases of clarithromycin resistance